Figure 2 Distribution of DEPDC5 variants in patients and controls

Slides:

Advertisements

Similar presentations

Schematic of the single variant polymorphism (SNP) genotyping assay.

Advertisements

Figure Pedigrees of the SCA42 families identified in this study

Holly A. Stessman, Raphael Bernier, Evan E. Eichler Cell

Figure 2 Sanger sequencing, conservation, and summary of known ACO2 mutations Sanger sequencing, conservation, and summary of known ACO2 mutations (A)

Figure 1 Summary of prior diagnostic workup in neuromuscular disorder cases Summary of prior diagnostic workup in neuromuscular disorder cases Percentage.

Figure Genomic and facial overview of the microduplications overlapping the GRIN2D gene found in the retrieved patients Genomic and facial overview of.

DOMINO: Using Machine Learning to Predict Genes Associated with Dominant Disorders Mathieu Quinodoz, Beryl Royer-Bertrand, Katarina Cisarova, Silvio.

Evolution of Populations: Part I

Figure Family pedigree and clinical improvement with riboflavin treatment Family pedigree and clinical improvement with riboflavin treatment (A) The proband.

Figure 2 Flow chart of patients who met the inclusion/exclusion criteria for the study Flow chart of patients who met the inclusion/exclusion criteria.

Volume 154, Issue 8, Pages (June 2018)

Figure 1 Allele frequency and effect size for ALS-associated genes

Figure 1. Type and distribution within KCNQ2 protein of variants in self-limiting epilepsy vs epileptic encephalopathy Type and distribution within KCNQ2.

Figure 1 Hierarchical clustering (HCL) outcome of all tested samples with the expression profile of the case report set as unknown Hierarchical clustering.

Figure 1 Spine MRI, sagittal and axial views of patients with idiopathic transverse myelitis with VPS37A mutations Spine MRI, sagittal and axial views.

Figure 2. Ophthalmologic findings of bialleic AP5Z1 mutations

Figure 1 Prediction of pathogenicity and protein localization of SBF1 mutations Prediction of pathogenicity and protein localization of SBF1 mutations.

Figure Revised Niemann-Pick disease type C (NP-C) diagnostic algorithm for the use of biomarkers and genetic testing Revised Niemann-Pick disease type.

Novel approach to genetic analysis and results in 3000 hemophilia patients enrolled in the My Life, Our Future initiative by Jill M. Johnsen, Shelley N.

Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

Figure 1 Genetic profile of 90 patients with dysferlin deficiency

Assessing the Pathogenicity, Penetrance, and Expressivity of Putative Disease-Causing Variants in a Population Setting Caroline F. Wright, Ben West,

Figure 1 Dominant and recessive missense and nonsense variants in neurofilament light (NEFL)‏ Dominant and recessive missense and nonsense variants in.

Figure WDR45 sequence changes in patients A and B

Table 4 Associations in SNP array data between the Braak stage and previously known AD risk loci (341 variants) comparing participants with Braak stage.

Figure 1 All patients with pediatric genetic movement disorders, their genetic diagnoses, and type of genetic investigations All patients with pediatric.

Figure 2 Schematic displaying the 3 described CHT mutant proteins alongside wild type molecule (Adapted from reference 2, using Microsoft Powerpoint Software)‏

Figure 2 LocusZoom plots

Figure 1 Time points of blood sampling

Figure 2 Linkage analysis of chromosome 19

Figure 1 Mutations in SPG7 in a family with primary lateral sclerosis

Figure 2 Lesion localization visualized in the top view of the model

Disrupted in Schizophrenia 1 (DISC1): Association with Schizophrenia, Schizoaffective Disorder, and Bipolar Disorder Colin A. Hodgkinson, David Goldman,

Figure Genetic deletion and MRI changes with EHMT1 deletion

Figure 3. Comparison of median manual muscle test scores in the upper and lower limbs Comparison of median manual muscle test scores in the upper and lower.

Figure Genomic and facial overview of the microduplications overlapping the GRIN2D gene found in the retrieved patients Genomic and facial overview of.

Figure 1 Within-groups sum of squares vs number of clusters Within-groups sum of squares vs number of clusters to determine the number needed for k-means.

Figure 2 Functionally significant genes

Table 2 Rs number, gene, OR, 95% CI, and permutation p value for the statistical significant variants resulted from allelic association analysis association.

Figure 1 JCV serostatus JCV serostatus (A) Serostatus of 1,921 natalizumab-treated patients with multiple sclerosis, with JCV− patients shown in black.

Figure 5 Pairwise correlations between selected patient-reported outcomes and performance tests in patients with MS (A) The number of pairwise correlations.

Aya Miyazaki et al. JACEP 2016;2:

Figure 4. Electron microscopic findings in AP-5 patient cells

Figure 1 Annual trend in specimen type submitted as first sample for aquaporin-4 immunoglobulin G testing (serum only vs CSF only vs both) from 101,065.

Figure 5 Autopsy Mycoplasma DNA analysis

Hunting for Celiac Disease Genes

Figure 1 Examples illustrating gating strategy for fluorescence-activated cell sorting (FACS)‏ Examples illustrating gating strategy for fluorescence-activated.

Figure 1 Kernel density plots

Figure 1 Pedigree and genetic findings

Figure 1 Mutated CTSF in adult-onset neuronal ceroid lipofuscinosis and patients with frontotemporal dementia Mutated CTSF in adult-onset neuronal ceroid.

Figure 1 Examination of MuSK antibody levels and B-cell subsetsFlow cytometric analysis (n = 13) using standardized Human Immunology Project Consortium.

Figure 1 Histamine flare in patients and controls

Figure 1 Percentage distribution according to severity of baseline behavioral changes in behavioral variant frontotemporal dementia (bvFTD) and semantic.

Figure 2. Patient stratification by the reported duration of symptoms and disease severity at the time of assessment Patient stratification by the reported.

Figure 2 Global tau-PET distribution in familial prion disease mirrors the distribution seen in Alzheimer disease Global tau-PET distribution in familial.

Figure 1 bvFTD PINBPA network

Figure 1 Schematic representation of FOXG1 gene, protein domain structure, and positions of FOXG1 mutations Schematic representation of FOXG1 gene, protein.

Distribution of podocyte gene mutations in patients with genetic congenital nephrotic syndrome (CNS) and steroid–resistant nephrotic syndrome (SRNS). Distribution.

A Novel Truncating Variant in FLNC-Encoded Filamin C May Serve as a Proarrhythmic Genetic Substrate for Arrhythmogenic Bileaflet Mitral Valve Prolapse.

Analysis of protein-coding genetic variation in 60,706 humans

Figure Joint tests of SNPs and vitamin D deficiency in CACNA1C and CACNA1D Joint tests of SNPs and vitamin D deficiency in CACNA1C and CACNA1D Each point.

Figure 2 Pedigrees of families and segregation analysis of variants c

Figure 1. Pedigree and clinical picture of the patient

Genetic Features of Chinese Patients with Gitelman Syndrome:

Figure 2 Compound heterozygous mutations in ADAM22

Figure 2 Striatal dopamine transporter binding with the SNCA A53E mutation Transaxial planes of [123I]FP-CIT SPECT on the striatal level are presented.

Figure 2 Interleukin-6 concentrations in the CSF In 2 mutation carriers (patient 1 in dark blue triangle and patient 5 in light blue triangle carrying.

Figure 1 Representative radiologic and pathologic images of patients with brain somatic mutations in SLC35A2 Representative radiologic and pathologic images.

Figure Genetic characterization of the novel GYG1 gene mutation (A) GYG1_cDNA sequence and position of primers used. Genetic characterization of the novel.

Concordance between the genomic landscape identified by whole-exome sequencing of plasma cfDNA and tumor; DNA and recurrence of KDR/VEGFR2 oncogenic mutations.

Presentation transcript:

Figure 2 Distribution of DEPDC5 variants in patients and controls Distribution of DEPDC5 variants in patients and controls Upper panel of the schematic shows all previously reported truncating mutations (black)1,2,8–13 and those described in this study (red). Lower panel shows all missense mutations in previous studies (black) and those described in this study (red), numbers in parentheses show the highest population MAF from the ExAC data set, and black lines show the missense variants present in ExAC and variable frequencies. Many of the missense mutations described in patients are present at appreciable frequencies in controls, and there are many missense variants across the gene. It will be vital to perform functional experiments to test the functional effect of these variants, to understand whether and how they cause disease, and to understand the incomplete penetrance that is a common feature of this disorder. ExAC = Exome Aggregation Consortium; MAF = minor allele frequency. Gemma L. Carvill et al. Neurol Genet 2015;1:e17 © 2015 American Academy of Neurology